Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical practice. Obsessive-compulsive disorder.

Literature DB >> 14724305

Clinical practice. Obsessive-compulsive disorder.

Michael A Jenike¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 14724305 DOI： 10.1056/NEJMcp031002

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

51 in total

1. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors: Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric
Journal: Psychopharmacology (Berl) Date: 2005-12-22 Impact factor: 4.530

2. Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder.

Authors: Panagiotis Oulis; Vasilios G Masdrakis; Evangelos Karapoulios; Nikolaos A Karakatsanis; Anastasios V Kouzoupis; George Konstantakopoulos; Constantin R Soldatos
Journal: Prim Care Companion J Clin Psychiatry Date: 2008

3. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding.

Authors: Christopher Pittenger; Thomas G Adams; Jean-Dominique Gallezot; Michael J Crowley; Nabeel Nabulsi; Hong Gao; Stephen A Kichuk; Ryan Simpson; Eileen Billingslea; Jonas Hannestad; Michael Bloch; Linda Mayes; Zubin Bhagwagar; Richard E Carson
Journal: J Affect Disord Date: 2016-02-09 Impact factor: 4.839

Review 4. Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics.

Authors: Jonathan T Ting; Guoping Feng
Journal: Curr Opin Neurobiol Date: 2011-05-24 Impact factor: 6.627

5. High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors: W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal: Neural Plast Date: 2010-02-18 Impact factor: 3.599

6. Transdiagnostic emotional vulnerabilities linking obsessive-compulsive and depressive symptoms in a community-based sample of adolescents.

Authors: Gregory S Chasson; Mariel S Bello; Alexandria M Luxon; Trevor A A Graham; Adam M Leventhal
Journal: Depress Anxiety Date: 2017-06-29 Impact factor: 6.505

Clinical practice. Obsessive-compulsive disorder.

1. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

2. Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder.

3. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding.

Review 4. Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics.

5. High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

6. Transdiagnostic emotional vulnerabilities linking obsessive-compulsive and depressive symptoms in a community-based sample of adolescents.

7. Glutamate and the Treatment of Obsessive-Compulsive Disorder.

Review 8. Brain imaging in pediatric obsessive-compulsive disorder.

9. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?

10. Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.